Nippon Shinyaku Co Ltd ADR (NPPNY PINK) stock market data APIs
$5.3148
0(0%)
as of July 18, 2025
Try our APIs with
free plan!
Nippon Shinyaku Co Ltd ADR Financial Data Overview
Price chart is built with
Anychart
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. Its Pharmaceuticals Business segment offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases. The company's Functional Food Business segments provides health food ingredients, preservatives, protein preparations, and sports and supplements. The company in the Strategic Partnership with Nippon Shinyaku will develop and commercialize for Mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Prev. Close
5.3148
Open
5.3148
High
5.3148
Low
5.3148
52 wk Range
5.13-6.9627
Market Cap
1 442 M
P/E Ratio
6.6049
Shares Outstanding
270 M
Revenue
160 232 M
EPS
59.44
Dividends (Yield)
0.0364
Beta
-0.277
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nippon Shinyaku Co Ltd ADR data using free add-ons & libraries
Get Nippon Shinyaku Co Ltd ADR Fundamental Data
Nippon Shinyaku Co Ltd ADR Fundamental data includes:
- Net Revenue: 160 232 M
- EBITDA: 42 944 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nippon Shinyaku Co Ltd ADR News
New
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Capricor Therapeutics FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for ...
NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases
PARAMUS, N.J., July 1, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), headquartered in Kyoto, Japan, has finaliz...
Cabral Gold Adds Third Drill Rig to Current Drill Program at the Cuiú Cuiú District, Brazil
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Cabral Gold Inc. (TSXV: CBR) (OTC: CBGZF) ("Cabral" or the "Company") is pleased to advise that it has added a third drill rig to th...
Cabral Gold Adds Third Drill Rig to Current Drill Program at the Cuiú Cuiú District, Brazil
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Cabral Gold Inc. (TSXV: CBR) (OTC: CBGZF) ("Cabral" or the "Company") is pleased to advise that it has added a third drill rig to th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
